CLINICAL TRIALS PROFILE FOR PRAMIPEXOLE DIHYDROCHLORIDE

All Clinical Trials for PRAMIPEXOLE DIHYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00025792 ↗	Clinical Trial of Pramipexole in Bipolar Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	2001-10-01	The purpose of this study is to examine the safety and effectiveness of the drug pramipexole given in combination with lithium or divalproex for the short-term treatment of acute depression in patients with bipolar disorder. Bipolar disorder is a severe, chronic, and often life-threatening illness. Treatments for acute unipolar depression have been extensively researched. However, despite the availability of a wide range of antidepressant drugs, a significant proportion of depressed patients fail to respond to first-line antidepressant treatment. Novel and improved therapeutics for bipolar depression are needed. This study will evaluate the antidepressant properties of pramipexole. This study will be conducted in three phases. Phase 1 is a 14-day washout period in which participants will be tapered off all their psychiatric medicines except divalproex or lithium. Participants will also be asked to adhere to a low caffeine and low monoamine diet. During Phase 2, participants will be randomly assigned to receive either pramipexole or placebo (an inactive pill) for 6 weeks. Participants who respond to treatment will be given either open-label pramipexole or another clinical treatment. Participants will be screened with a medical history, physical examination, electrocardiogram (EKG), blood and urine tests, and a psychiatric evaluation. Women of childbearing potential will have a pregnancy test. Participants will have a physical exam and EKG at study entry and study completion. Blood will be drawn at various times throughout the study. Pulse and blood pressure measurements will be taken daily. Weekly interviews will be conducted. Participants and a control group of healthy volunteers will undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain.
NCT00086294 ↗	ACP-103 to Treat Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2004-06-25	This study will evaluate the effects of an experimental drug called ACP-103 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term levodopa treatment. ACP-103 changes the spread of certain brain signals that are affected in patients with Parkinson's disease. Patients with relatively advanced Parkinson's disease and dyskinesias who are between 30 and 80 years of age may be eligible for this study. Candidates are screened with a complete medical history and physical examination, neurological evaluation, blood and urine tests, and electrocardiogram (ECG). A brain magnetic resonance imaging (MRI) scan, CT scan, and chest x-ray may be done if medically indicated. Patients enrolled in the study will, if possible, stop taking all antiparkinsonian medications for one month (2 months for Selegiline) before the study begins and throughout its duration. Exceptions are Sinemet (levodopa/carbidopa), Mirapex (pramipexole) and Requip (ropinirole). Levodopa Dose Finding After the screening evaluations, patients are admitted to the NIH Clinical Center for 2 to 3 days to undergo a levodopa "dose-finding" procedure. For this test, patients stop taking Sinemet and instead have levodopa infused through a vein. During the infusion, the drug dose is increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Side effects are monitored closely during the infusions, and parkinsonian symptoms are evaluated frequently during and after the infusions. The infusions usually begin early in the morning and continue until evening. Once the infusion is finished, patients resume taking their regular oral Sinemet dose. The infusions are repeated once a week during 1-day inpatient evaluations. Treatment Patients are randomly assigned to take either ACP-103 followed by placebo (a look-alike pill with no active ingredient) once a week for 10 weeks or vice versa (placebo followed by ACP-103). Patients are admitted to the Clinical Center for each dose. During this admission they have a brief medical examination, blood and urine tests, ECG, and review of symptoms or changes in their condition. They also have an infusion of levodopa (see above) at the previously determined optimal rate. Parkinsonism symptoms and dyskinesias are evaluated every 30 minutes for about 6 hours. At the end of the infusions and ratings, patients are discharged home with their regular Parkinson's medications until the following visit. Two weeks after their final dose of ACP-103 or placebo, patients are contact by telephone for a follow-up safety check. At that time, the investigator may ask the patient to return to the clinic for closer evaluation.
NCT00086307 ↗	Lexapro and Pramipexole and to Treat Major Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	2004-06-01	This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone. Purpose: Patients between 18 and 65 years of age with Major Depressive Disorder without psychotic features may be eligible for this 9-week study. Candidates must currently be in a major depressive episode of at least 4 weeks' duration, have failed to respond to treatment with an SSRI (Prozac, Zoloft, Paxil, Luvox, Celexa), and not have failed to respond to more than four antidepressants for the current episode. Candidates are screened with a physical examination, psychiatric evaluation, blood tests, review of vital signs, height and weight measurements, electrocardiogram (ECG), urine test for illegal drugs, and pregnancy test for women. Participants are tapered off antidepressants or other medications prohibited during the study and remain drug-free for 1 week before starting treatment. They are then randomly assigned to take pramipexole and escitalopram, pramipexole alone, or escitalopram alone for 6 weeks. During the study, participants come to the clinic eight times for health assessments and symptoms assessments, which include a check of vital signs and rating scales for depression and anxiety, adverse events, and sexual functioning. Blood and urine samples are collected periodically to monitor health, detect pregnancy in women, and detect illicit drug use. At the end of the 6-week treatment period, participants have a physical examination, ECG, blood test, and check of vital signs. Short-term anti-depressant treatment is offered, and plans are made for long-term treatment. Atendemos pacientes de habla hispana. ...
NCT00096720 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease	Completed	Boehringer Ingelheim	Phase 2	2004-02-01	Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.

Clinical Trial Conditions for PRAMIPEXOLE DIHYDROCHLORIDE

Condition Name

Condition Name for PRAMIPEXOLE DIHYDROCHLORIDE
Intervention	Trials
Parkinson Disease	36
Restless Legs Syndrome	24
Healthy	11
Depression	10

Condition MeSH

Condition MeSH for PRAMIPEXOLE DIHYDROCHLORIDE
Intervention	Trials
Parkinson Disease	53
Restless Legs Syndrome	25
Psychomotor Agitation	24
Syndrome	23

Clinical Trial Locations for PRAMIPEXOLE DIHYDROCHLORIDE

Trials by Country

Trials by Country for PRAMIPEXOLE DIHYDROCHLORIDE
Location	Trials
United States	325
Germany	34
Spain	14
United Kingdom	11
Austria	11

Trials by US State

Trials by US State for PRAMIPEXOLE DIHYDROCHLORIDE
Location	Trials
New York	21
California	21
Massachusetts	19
Florida	17
Georgia	16

Clinical Trial Progress for PRAMIPEXOLE DIHYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for PRAMIPEXOLE DIHYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	4
Phase 4	28

Clinical Trial Status

Clinical Trial Status for PRAMIPEXOLE DIHYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	90
RECRUITING	7
Unknown status	7

Clinical Trial Sponsors for PRAMIPEXOLE DIHYDROCHLORIDE

Sponsor Name

Sponsor Name for PRAMIPEXOLE DIHYDROCHLORIDE
Sponsor	Trials
Boehringer Ingelheim	57
National Institute of Mental Health (NIMH)	8
Region Skane	3

Sponsor Type

Sponsor Type for PRAMIPEXOLE DIHYDROCHLORIDE
Sponsor	Trials
Industry	85
Other	82
NIH	11

Last updated: July 26, 2026

Pramipexole dihydrochloride clinical trials update, market analysis, and revenue projection (Parkinson’s and restless legs)

Pramipexole dihydrochloride is a marketed dopamine agonist used for Parkinson’s disease (PD) and restless legs syndrome (RLS). Current market dynamics are driven by (1) patent/market-exclusivity timelines that vary by brand and filing jurisdiction, (2) steady generic penetration across major markets, and (3) ongoing clinical-line extensions that focus on tolerability, dosing optimization, and patient-relevant endpoints rather than new chemical entities. The near-term revenue outlook is mostly a function of generic share, payer behavior, and safety-driven prescribing constraints rather than new trial “breakthroughs.”

What is pramipexole dihydrochloride used for and what clinical evidence supports PD and RLS?

Pramipexole is a non-ergot dopamine agonist (D2/D3 receptor affinity) prescribed for:

• PD: treatment of idiopathic Parkinson’s disease, including symptom control (monotherapy and adjunct to levodopa in many regimens).
• RLS: reduction of sensory discomfort and urge to move in appropriately diagnosed patients.

Which clinical trial endpoints matter for pramipexole in PD?

Typical PD studies and label-supported programs emphasize:

• Motor symptom scales (classically UPDRS-related measures)
• Time to worsening or “off” time metrics in dopaminergic regimens
• Functional outcomes tied to patient-relevant motor control

Which clinical trial endpoints matter for pramipexole in RLS?

Typical RLS programs and post-approval studies emphasize:

• International Restless Legs Syndrome Study Group (IRLS) scale changes
• Sleep-related endpoints (sleep disturbance, onset latency)
• Durability of response across follow-up intervals

What safety signals shape prescribing and trial design?

Dopamine agonists are clinically monitored for:

• Somnolence and sudden sleep onset
• Hallucinations and confusion (especially in older PD populations)
• Impulse control disorders
• Edema and orthostatic hypotension These safety domains strongly influence tolerability arms, titration schedules, and risk-management messaging in later-generation studies.

What is the latest pramipexole dihydrochloride clinical trials update (registrations, phases, and study focus)?

A complete, current “latest update” requires live registry pulls (ClinicalTrials.gov and EudraCT for Europe). Under the constraint that no new external registry data is provided in this prompt, an exhaustive and date-accurate trial-by-trial update cannot be produced without introducing factual gaps.

Which pramipexole dihydrochloride formulations are used commercially and how do they affect clinical and regulatory strategies?

Pramipexole is sold in immediate-release forms and, in some jurisdictions, extended-release options depending on approved products and label-specific dosing.

How do immediate-release vs extended-release products change trial design?

• PK alignment: extended-release programs often focus on steady-state exposure and reduced peak-trough variability.
• Endpoint cadence: sustained symptom control over a dosing interval is emphasized.
• Safety: somnolence and GI adverse events can shift with exposure profiles, driving titration and monitoring protocols.

What formulation types are relevant for IP and ANDA strategy?

Even after the API becomes generic, manufacturers build product differentiation around:

• Bioequivalence strategy for specific strengths
• Manufacturing process control (granulation, milling, blending, dissolution performance)
• Drug product stability and dissolution specifications to support generic approval

What is the pramipexole dihydrochloride market size and growth outlook by indication?

A precise market size and forecast requires current sales datasets (e.g., IQVIA, SSR Health, or payer claims) that are not included in the prompt. With no market numbers provided, a quantified projection would be fabricated.

How do generic launches and payer formularies affect pramipexole revenue?

Even without numeric market shares, the revenue model for pramipexole is structurally shaped by:

• High generic penetration in most markets once primary patents expire.
• Payer preference for lowest-cost equivalent products.
• Brand consolidation in countries where brand still persists or where extended-release formats maintain differentiation.

What are the typical drivers of generic share loss or retention?

• Tight substitution controls around specific dose strengths or patient response history
• Real-world tolerability differences among generics, even when bioequivalence is demonstrated
• Coverage restrictions for specific formulations (immediate-release vs extended-release)
• Contract pharmacy and PBM price dynamics

When does pramipexole dihydrochloride lose exclusivity and what does that imply for generic entry risk?

Exclusivity timelines vary materially by:

• Brand name product
• Jurisdiction (US, EU, UK, other markets)
• Formulation (immediate vs extended release)
• Patent family scope (composition vs method-of-use vs formulation vs process)

A jurisdiction-level exclusivity and expiration analysis requires Orange Book/Bolar listing and national patent publication data. No such dataset is provided in the prompt, so a precise “date table” cannot be produced.

What patents protect pramipexole dihydrochloride and how many are typically in the estate?

In many markets, pramipexole’s core API is old enough that:

• Primary composition-of-matter exclusivity has largely run out.
• Patent estates concentrate in formulation variants, controlled-release approaches, specific dosing regimens, and manufacturing/process patents, plus method-of-use claims tied to clinical effect demonstrations.

A definitive “how many patents” answer depends on a patent search across jurisdictions and a product-to-patent mapping to current Orange Book listings or equivalent national registers. That mapping is not provided in the prompt.

What is the Orange Book status of pramipexole dihydrochloride and which ANDAs have Paragraph IV challenges?

Orange Book status and Paragraph IV litigation require specific listing and litigation docket data. No Orange Book listing records, Orange Book NDA numbers, or FDA litigation artifacts are provided, so a correct status table cannot be generated.

What patent litigation affects pramipexole dihydrochloride (US) and where do disputes concentrate?

Patent litigation for an established dopamine agonist typically concentrates in:

• Formulation or extended-release delivery claims
• Bioequivalence and infringement-by-composition disputes tied to formulation composition and manufacturing process
• Method-of-use allegations when labels include specific therapeutic regimens

A fact-based litigation update requires case numbers, filing dates, and outcomes. None are provided, so a litigation section would be non-factual.

How does pramipexole dihydrochloride compare with ropinirole and rotigotine on efficacy, tolerability, and market dynamics?

For business planning, pramipexole competes with:

• Ropinirole (oral dopamine agonist)
• Rotigotine (transdermal dopamine agonist)

What differences typically matter in switching behavior?

• Route preference: transdermal rotigotine can shift adherence patterns and GI tolerability profiles.
• Sleepiness and hallucinations risk management: specific titration and patient selection differ across agents.
• Coverage and price: payer contracts often determine first-line access, not just clinical trial superiority.

A quantified comparative market analysis needs revenue and share data that is not provided.

What generic entry risks exist for pramipexole dihydrochloride extended-release vs immediate-release?

Generic risk analysis depends on:

• Remaining patent coverage by product presentation
• Whether a generic applicant must use different formulation constraints to achieve dissolution targets
• Litigation history and settlement precedent

Without product-level patent mapping and FDA approval histories, a correct entry-risk assessment cannot be completed.

What is the regulatory status of pramipexole dihydrochloride (US FDA and EU approvals), including labeling trends?

Regulatory status includes:

• FDA approvals (NDA/ANDA history)
• Label evolution around safety warnings and patient monitoring
• Post-marketing requirements and risk evaluation plans

A complete regulatory status update requires label versions and approval records by specific NDA/ANDA. None are provided in the prompt.

Commercial projection: what revenue range is reasonable for pramipexole dihydrochloride over the next 3 to 5 years?

A quantitative projection requires:

• Current annual revenue base
• Volume trends (prescriptions, dose units)
• Net price erosion assumptions under generic competition
• Country mix and formulation mix (IR vs ER)
• Competitive and payer contract changes

Those inputs are not present. Producing numeric projections would not meet the precision standard expected for patent and market decision-making.

---

Key Takeaways

• Pramipexole dihydrochloride is an established dopamine agonist in PD and RLS with a clinical and commercial profile dominated by long-term safety monitoring and generic price competition.
• Market and revenue projections are driven by generic share, payer formularies, and formulation mix rather than new-drug growth.
• A fact-accurate “clinical trials update,” Orange Book status, Paragraph IV landscape, and patent-expiration timeline require product- and jurisdiction-specific dataset inputs that are not included in the prompt.

FAQs

1. Is pramipexole dihydrochloride still under patent protection in the US for immediate-release and extended-release products?
2. Do pramipexole formulation differences (IR vs ER) change bioequivalence requirements for generic approval?
3. What RLS trial endpoints are most used for dopamine agonist dose optimization and label support?
4. How do impulse control disorder and hallucination risks influence prescribing and risk-management language in pramipexole labels?
5. What market factors most strongly determine net price erosion for legacy oral generics like pramipexole?

References

No sources were provided in the prompt, and no external registry or database results were included, so no citations can be listed.